RESUMO
The efficacy and safety of interferon alfa-2a monotherapy was evaluated in seventeen Nigeria patients with chronic myelogenous leukaemia (CML). Male and female patients with a mean age of 34.5 +/- 10.6 years were recruited into the study. Interferon therapy was administered at a maintenance dose of 9 MIU daily for 12 months. Efficacy was evaluated by assessing both haematologic and cytogenetic response, tolerability by incidence of adverse events and safety by laboratory haematological and biochemical indices. At the end of 12 months of therapy 6 patients (54.4%) had complete haematologic remission whilst 3 patients (100% of those evaluated) showed partial cytogenetic remission. The incidence of adverse event was 70% and the monitored haematologic and biochemical indices were not adversely affected by treatment. In conclusion, the study clearly demonstrated a significant benefit of interferon alpha-2a in the management of Nigerian patients with CML. The changes in the haematological and cytogenetic profiles between baseline and term were significant (p < 0.05). However, it is imperative and important to encourage and continue monitoring of the responding and stabilized patients beyond 12 months in order to demonstrate sustained response. The drug was reasonably well tolerated, however life threatening pancytopenia may pose a major problem in certain cases.
Assuntos
Antineoplásicos/uso terapêutico , Interferon-alfa/uso terapêutico , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Adulto , Antineoplásicos/farmacologia , Exame de Medula Óssea , Citogenética , Monitoramento de Medicamentos , Feminino , Humanos , Interferon alfa-2 , Interferon-alfa/farmacologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/sangue , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Masculino , Pessoa de Meia-Idade , Nigéria , Pancitopenia/induzido quimicamente , Projetos Piloto , Proteínas Recombinantes , Indução de Remissão , Segurança , Resultado do TratamentoRESUMO
Cytogenetic studies were carried out on the blood/bone marrow samples of three patients with chronic granulocytic leukaemia (CGL) and one patient with Burkitt's lymphoma. The karyotypes determined were 46, XY, Ph+ for patient O. A; 46, XY, t(9q+, 22q) for T. A. and 46, XX, t(9q+, 22q) for patient E. O. Patient O. L. with Burkitt's lymphoma presented two karyotypes: 46, XY and 46, XY, +18. The results showed that Philadelphia (Ph1) chromosome was detected in all the patients with CGL and a chromosome marker for African Burkitt's lymphoma in the boy with the disease.
Assuntos
Linfoma de Burkitt/genética , Aberrações Cromossômicas/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Adulto , Exame de Medula Óssea , Linfoma de Burkitt/sangue , Linfoma de Burkitt/diagnóstico , Criança , Feminino , Marcadores Genéticos , Humanos , Cariotipagem , Leucemia Mielogênica Crônica BCR-ABL Positiva/sangue , Leucemia Mielogênica Crônica BCR-ABL Positiva/diagnóstico , Masculino , Pessoa de Meia-Idade , Nigéria , Cromossomo FiladélfiaRESUMO
The nature and mode of inheritance of resistance to Helminthosporium maydis blight was investigated in two maize varieties, 'RbU-W' and 'DIC'. The study of F1, F2, and reciprocal backcross populations of crosses between these two varieties on the one hand and two susceptible varieties, 'UVE' and 'ZPSc-58c' on the other, revealed that resistance in the two varieties is monogenic recessive. The genes for resistance in the two varieties are allelic. Resistance was shown to be a lesion-type and measurements revealed that it operated through reduced lesion size and lesion number.
